Communiqués Xspray Pharma AB

Actions

XSPRAY

SE0009973563

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq Stockholm 18:00:00 29/09/2026			Varia. 5j.	Varia. 1 janv.
9,950 ^SEK	+3,22%		+8,15%	-68,36%

17:06	Le directeur général de Xspray Pharma achète des actions pour près de 0,5 million de couronnes	FW
23/09	Xspray Pharma présentera des données sur la LMC pour Dasynoc et Nilopki	FW

Communiqués

23/09	Xspray Pharma to present CML data supporting differentiation of Dasynoc and Nilopki	AQ
15/09	Xspray Pharma invites to Investor Update in Gothenburg	AQ
19/08	Xspray Pharma invites to a conference call following receipt of CRL for Dasynoc	AQ
19/08	Flerie’s portfolio company Xspray Pharma receives CRL from FDA for Dasynoc®	AQ
19/08	Xspray Pharma receives Complete Response Letter (CRL) from FDA for Dasynoc	AQ
06/08	Xspray Pharma (Q2 review): Just ahead of Dasynoc PDUFA	AQ
05/08	Xspray Pharma Interim Report Second Quarter 2026	AQ
26/06	Xspray Pharma provides regulatory update on its US product candidates Nilopki® and Dasynoc® and notes continued progress with its third-party manufacturer NerPharMa	AQ
05/06	Xspray Pharma to host a conference call regarding Nilopki™	AQ
05/06	Flerie’s portfolio company Xspray Pharma receives CRL from FDA for Nilopki™	AQ
05/06	Xspray Pharma Receives CRL from U.S. FDA for Nilopki™	AQ
03/06	Xspray Pharma employees fully participate in market priced long term incentive programs, signaling strong confidence ahead	AQ
12/05	Bulletin from the annual general meeting of Xspray Pharma AB (publ) 12 May 2026	AQ
30/04	New number of shares and votes in Xspray Pharma after new share issue April 2026	AQ
28/04	Interim Report First Quarter 2026	AQ
23/04	Xspray’s rights issue oversubscribed – over-allotment issue fully utilized	AQ
14/04	FDA accepts trade name Nilopki® for Xspray's drug candidate XS003 (nilotinib)	AQ
09/04	Notice of annual general meeting of Xspray Pharma AB (publ)	AQ
31/03	Xspray publishes disclosure document regarding rights issue	AQ
26/03	Xspray receives additional subscription undertakings; rights issue now covered to 110% and over-allotment issue increased	AQ
26/03	Xspray Pharma publishes its Annual Report 2025	AQ
24/03	Xspray resolves on a rights issue of approximately SEK 83 million with an over-allotment issue	AQ
11/03	Xspray Pharma: FDA accepts resubmitted application for market approval of Dasynoc® – PDUFA date August 25, 2026	AQ
27/02	Flerie’s portfolio company Xspray Pharma appoints Blake Leitch as CEO and resubmits application for market approval of Dasynoc® to the FDA	AQ
26/02	Xspray Pharma re-submits its FDA application for Dasynoc	AQ